Mr Sandeep Athalye | Vice President and Head CDMA, Biosimilars
Boehringer Ingelheim

Clinical leadership in taking novel and biosimilar programs from all phases of development through registration in US, EU and ROW

Specialties: MD, Phase I -III clinical development, proof of concept, translational medicine, respiratory, oncology, biologics, Asia development operations expertise, management of >20 scientists, strategic focus in clinical development plans, optimising efficiency/productivity, focus on quality and cost, supporting a robust pipeline of drugs and timely regulatory submissions.